The invention provides an isolated, dual-specific antibody, or an antigen-binding portion thereof, which is specific for human IL-1αand human IL-1β. The dual specific antibodies of the invention also neutralize both human IL-1αand human IL-1β. The invention also provides domain antibodies (dAbs) specific for human IL-1αand human IL-1β.